Seaport Therapeutics (SPTX), a Boston-based biotech developing drugs to treat major depression, increased its IPO’s size at pricing – to 14.16 million shares – up from 11.8 million in the prospectus – and priced its IPO at $18.00 – the top of its range – to raise $254.88 million on Thursday night, April 30, 2026.
Shares of Seaport Therapeutics shot up $3.00 – or 16.67 percent – to open at $21.00 when they started trading today – Friday, May 1, 2026 – on the NASDAQ. Volume: 853,525 shares on that opening trade.
Seaport Therapeutics closed Friday, May 1, 2026, at $19.84 – up $1.84 from its IPO price for a 10.22 percent gain in its first day of NASDAQ trading. Volume: 4.69 million shares.
Goldman Sachs, J.P. Morgan, Leerink Partners, Citigroup and Stifel are the joint book-runners.
At pricing, Seaport Therapeutics had a market cap of $954.5 million.
Seaport Therapeutics (SPTX) intends to use the IPO’s proceeds to help fund the Phase 2 clinical trials of its leading drug candidates, GlyphAllo (SPT-300) and GlyphAgo (SPT-320), to treat major depression, including postpartum depression.
The company is not profitable.
(For more information about this company, please check the IPO Calendar and the individual IPO Profile found on the IPOScoop.com website.)
Note: Never trade on proposed symbols. They have been known to change and you might buy something on the OTC Bulletin Board.
To see what time the NASDAQ IPOs are expected to trade, please log in to: NASDAQTrader.com then scroll down to IPO Message.
Disclosure: Nobody on the IPOScoop.com staff has a position in any stocks mentioned above, nor do they trade or invest in IPOs. The IPOScoop.com staff does not issue advice, recommendations or opinions.